143 related articles for article (PubMed ID: 15460171)
1. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
Hendrix CW; Wakeford J; Wire MB; Lou Y; Bigelow GE; Martinez E; Christopher J; Fuchs EJ; Snidow JW
Pharmacotherapy; 2004 Sep; 24(9):1110-21. PubMed ID: 15460171
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
3. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
Goujard C; Vincent I; Meynard JL; Choudet N; Bollens D; Rousseau C; Demarles D; Gillotin C; Bidault R; Taburet AM
Antimicrob Agents Chemother; 2003 Jan; 47(1):118-23. PubMed ID: 12499178
[TBL] [Abstract][Full Text] [Related]
4. Effects of didanosine formulations on the pharmacokinetics of amprenavir.
Shelton MJ; Giovanniello AA; Cloen D; Berenson CS; Keil K; DiFrancesco R; Hewitt RG
Pharmacotherapy; 2003 Jul; 23(7):835-42. PubMed ID: 12885096
[TBL] [Abstract][Full Text] [Related]
5. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
6. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone.
Smith PF; Kearney BP; Liaw S; Cloen D; Bullock JM; Haas CE; Yale K; Booker BM; Berenson CS; Coakley DF; Flaherty JF
Pharmacotherapy; 2004 Aug; 24(8):970-7. PubMed ID: 15338845
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.
Tran JQ; Petersen C; Garrett M; Hee B; Kerr BM
Clin Pharmacol Ther; 2002 Dec; 72(6):615-26. PubMed ID: 12496743
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
[TBL] [Abstract][Full Text] [Related]
9. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.
Khalilieh S; Yee KL; Sanchez RI; Vaynshteyn K; Fan L; Searle S; Bouhajib M; Iwamoto M
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):151-161. PubMed ID: 31120195
[TBL] [Abstract][Full Text] [Related]
11. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
12. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.
Brophy DF; Israel DS; Pastor A; Gillotin C; Chittick GE; Symonds WT; Lou Y; Sadler BM; Polk RE
Antimicrob Agents Chemother; 2000 Apr; 44(4):978-84. PubMed ID: 10722500
[TBL] [Abstract][Full Text] [Related]
14. Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Moore K; Magee M; Sevinsky H; Chang M; Lubin S; Myers E; Ackerman P; Llamoso C
Br J Clin Pharmacol; 2019 Aug; 85(8):1771-1780. PubMed ID: 30980734
[TBL] [Abstract][Full Text] [Related]
15. Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy.
Joseph D; Schobelock MJ; Riesenberg RR; Vince BD; Webster LR; Adeniji A; Elgadi M; Huang F
Antimicrob Agents Chemother; 2015 Jan; 59(1):498-504. PubMed ID: 25385094
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.
Sadler BM; Gillotin C; Lou Y; Stein DS
Antimicrob Agents Chemother; 2001 Jan; 45(1):30-7. PubMed ID: 11120940
[TBL] [Abstract][Full Text] [Related]
17. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.
Crauwels HM; van Heeswijk RP; Vandevoorde A; Buelens A; Stevens M; Hoetelmans RM
J Clin Pharmacol; 2014 Feb; 54(2):133-40. PubMed ID: 24203510
[TBL] [Abstract][Full Text] [Related]
18. Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.
Moreira SA; Morcos PN; Navarro MT; Bech N; Smith PF; Brennan BJ
Pharmacotherapy; 2014 Mar; 34(3):220-6. PubMed ID: 23946152
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance.
Bruce RD; Winkle P; Custodio JM; Wei X; Rhee MS; Kearney BP; Ramanathan S; Friedland GH
Antimicrob Agents Chemother; 2013 Dec; 57(12):6154-7. PubMed ID: 24080665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
